NCT01912404View on ClinicalTrials.gov

Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Alcoholic Hepatitis
Interventions
DRUG

IDN-6556

25 mg BID for 28 days

DRUG

Placebo

Placebo controlled

Trial Locations (3)

23298

Virginia Commonwealth University, Richmond

46202

Indiana University, Indianapolis

55905

Mayo Clinic, Rochester

Sponsors
All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Conatus Pharmaceuticals Inc.

INDUSTRY

NCT01912404 - Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy | Biotech Hunter | Biotech Hunter